Compare · PODD vs SYK
PODD vs SYK
Side-by-side comparison of Insulet Corporation (PODD) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PODD and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $112.48B, about 11.7x PODD ($9.62B).
- Over the past year, PODD is down 55.8% and SYK is down 21.3% - SYK leads by 34.4 points.
- SYK has been more active in the news (8 items in the past 4 weeks vs 7 for PODD).
- Both have 25 recent analyst ratings on file.
- Company
- Insulet Corporation
- Stryker Corporation
- Price
- $141.09+1.60%
- $294.69+0.46%
- Market cap
- $9.62B
- $112.48B
- 1M return
- -0.33%
- +5.16%
- 1Y return
- -55.76%
- -21.34%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2007
- News (4w)
- 7
- 8
- Recent ratings
- 25
- 25
Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest PODD
- Insulet Announces Omnipod Discover Now Available in U.S.
- Barclays initiated coverage on Insulet with a new price target
- SEC Form 4 filed by Insulet Corporation
- Director Mazelsky Jonathan Jay was granted 141 shares, increasing direct ownership by 10% to 1,496 units (SEC Form 4)
- Director Huffines Robert Luther was granted 178 shares, increasing direct ownership by 7% to 2,627 units (SEC Form 4)
- Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
- Insulet Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
- Insulet Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Insulet Corporation filed SEC Form 8-K: Leadership Update
Latest SYK
- Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
- Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
- Barclays initiated coverage on Stryker with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker announces leadership succession
- Stryker to announce third quarter 2026 financial results
- VP, Chief Financial Officer Wells Preston Wendell disposed of 109 shares, decreasing direct ownership by 3% to 3,661 units (SEC Form 4)
- VP, Chief Financial Officer Wells Preston Wendell disposed of 2,739 shares, decreasing direct ownership by 42% to 3,770 units (SEC Form 4)
- Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
- New insider Baculik Emily Kay claimed ownership of 1,554 shares (SEC Form 3)